MAGE-A3 271-279
FLWGPRALV melanoma/cancer-testis epitope
9 Amino Acids · MW: 1009.2
Amino Acids
9
Molecular Weight
1009.2
Half-life
<1 h
Research Score
4.2
Studies
80
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is MAGE-A3 271-279?
An HLA-A2-restricted peptide derived from the MAGE-A3 cancer-testis antigen. It is used in therapeutic vaccine research to expand tumor-reactive cytotoxic T cells.
Key Benefits & Mechanisms
tumor-antigen targeting
CD8 T-cell priming
vaccine platform
Research Summary
MAGE-A3 epitopes have been studied across multiple solid tumors because MAGE antigens are largely absent from normal adult tissues. The peptide is a common component in experimental cancer vaccines and immune-monitoring assays.
Related Peptides
GV1001
Human telomerase reverse transcriptase (hTERT) 611-626 peptide GV1001
A telomerase-derived 16-mer peptide developed as a cancer vaccine antigen. It is designed to trigger T-cell responses against hTERT-expressing tumors.
Cancer ResearchNelipepimut-S
HER2/neu-derived peptide vaccine Nelipepimut-S (E75; KIFGSLAFL)
A 9-mer HLA-A2/A3-restricted peptide from HER2/neu used as a vaccine antigen. It aims to expand cytotoxic T-cell responses against HER2-positive tumors.
Cancer ResearchWT1 peptide
Wilms tumor 1 (WT1) antigen-derived peptide RMFPNAPYL
A WT1-derived 9-mer peptide used in peptide-vaccine strategies for leukemias and solid tumors. It is intended to generate HLA-restricted cytotoxic T-cell responses against WT1-positive cancer cells.
Cancer ResearchSurvivin 2B peptide
Survivin 2B peptide (LMLGEFLKL)
A survivin-derived HLA-A24-restricted epitope investigated as a peptide vaccine antigen. It targets survivin, a frequently overexpressed inhibitor of apoptosis in tumors.
Cancer Research